CEM and AmbioPharm, two firms based in the Carolinas, have formed a partnership for the production of GMP peptides for the pharmaceutical industry. Under this, AmbioPharm will have exclusive rights to use CEM’s large-scale microwave technology for solid-phase peptide synthesis (SPPS) at up to multi-kilogram quantities using proprietary scalable reactors.